Home
    • Plans Blog Contact
    Enveric Biosciences Inc logo

    Enveric Biosciences Inc

    ENVB
    Last price US$1.27
    Market cap US$2.6m
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Enveric Biosciences Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. It has created a portfolio of new chemical entities for specific mental health indications using The Psybrary, a discovery and development platform. The company's lead program is the EVM201 series that comprise next generation synthetic psilocybin analogues that are considered prodrugs of the active metabolite psilocin. It is also advancing its third generation of therapeutics, the EVM301 Series, for treating central nervous system disorders. The company is headquartered in Naples, Florida with offices in Cambridge, Massachusetts and Calgary, Canada. Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. It has created a portfolio of new chemical entities for specific mental health indications using The Psybrary, a discovery Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Enveric Biosciences Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 15, 2026

    Quarterly result summary

    EPS was $1.08 (reported).

    EPS $1.08 reported

    What changed

    • EPS reported to $1.08.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings material Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 15, 2026 SEC filing 8-K May 15, 2026 SEC filing 10-K Mar 27, 2026 SEC filing 8-K Mar 27, 2026 Earnings release Earnings release Mar 27, 2026 SEC filing 8-K Nov 14, 2025 SEC filing 10-Q Nov 14, 2025 Earnings material Earnings release Nov 14, 2025 SEC filing 8-K Aug 14, 2025 Earnings material Earnings release Aug 14, 2025 SEC filing 10-Q Aug 14, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Enveric Biosciences Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score -0.74/5
    Enveric Biosciences Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Enveric Bios... ENVB US$2.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.10/5
    Enveric Biosciences Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Enveric Bios... ENVB US$2.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 2.28/5
    Enveric Biosciences Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Enveric Bios... ENVB US$2.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Enveric Biosciences Inc logo

    Enveric Biosciences Inc

    US$1.27

    US$2.6m

    -4.85%

    N/A